剛性連接子通過(guò)引入環(huán)（脂肪環(huán)、脂肪雜環(huán)、芳香環(huán)等）來(lái)替代線性連接子，可以有效減少藥物分子中可旋轉(zhuǎn)鍵數(shù)量，限制化合物構(gòu)象，從而有利于提高藥物分子對(duì)靶點(diǎn)的結(jié)合穩(wěn)定性；另一方面，剛性環(huán)相比線性分子更容易調(diào)節(jié)藥物分子的物理化學(xué)性質(zhì)，改善其DMPK，目前在蛋白降解劑類藥物中得到廣泛應(yīng)用。
2-(4-Aminocyclohexyl)ethanol
2-(4-(4-Aminophenyl)piperazin-1-yl)ethanol
Methyl 4-(2-hydroxyethyl)benzoate
tert-Butyl 4-(4-aminophenoxy)piperidine-1-carboxylate
1,2-Bis(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethane
1-Cbz-4-(aminomethyl)piperidine
3-(Methoxycarbonyl)bicyclo[1.1.1]pentane-1-carboxylic acid
2-(4-(((tert-Butoxycarbonyl)amino)methyl)phenyl)acetic acid
1-(2-N-Boc-Aminoethyl)piperazine
(4-(((tert-Butoxycarbonyl)amino)methyl)phenyl)boronic acid
Methyl 4-(hydroxymethyl)bicyclo[2.2.2]octane-1-carboxylate
tert-Butyl 6-formyl-2-azaspiro[3.3]heptane-2-carboxylate
tert-Butyl ((3-oxocyclobutyl)methyl)carbamate
tert-Butyl ((4-fluoropiperidin-4-yl)methyl)carbamate
cis-3-(Aminomethyl)cyclobutanol hydrochloride
2-(Piperidin-4-yl)ethanol
3-(Piperazin-1-yl)propan-1-ol
Methyl 3-aminobicyclo[1.1.1]pentane-1-carboxylate
1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl)piperazine
4-(4-(2-Hydroxyethyl)piperazin-1-yl)butane-1-sulfonic acid
N-(2-Aminoethyl)-4-piperidinol
trans-3-Aminocyclobutanecarboxylic acid
cis-3-Aminocyclobutanecarboxylic acid
4-(1-(tert-Butoxycarbonyl)piperidin-4-yl)benzoic acid
tert-Butyl 2-azaspiro[4.5]decan-8-ylcarbamate
Methyl 2-(3-(hydroxymethyl)cyclobutyl)acetate
2-(Piperidin-4yl)acetic acid hydrochloride
1-Boc-3-((Methylamino)methyl)azetidine
tert-Butyl 7-azaspiro[3.5]nonan-2-ylcarbamate
